En open-label pilotundersøgelse af VTX2735 i tilbagevendende pericarditis
En fase 2A, open-label-pilotundersøgelse for at evaluere sikkerheden/tolerabiliteten, effektiviteten, farmakokinetikken og farmakodynamikken af VTX2735 hos deltagere med tilbagevendende pericarditis
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).
Cohort A will include approximately 10 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A
- A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A
- An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Cohort B will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C
- A 14-day Follow-Up Period
Cohort C will include approximately 20 participants and will consist of the following:
- A 30-day Screening Period (to see if a participant qualifies for the study)
- A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B
- An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B
- A 14-day Follow-Up Period
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Ventyx Clinical Trial Contact
- Telefonnummer: ext 108 888-411-5176
- E-mail: ClinicalTrials@ventyxbio.com
Studiesteder
-
-
-
Ghent, Belgien, 9000
- Rekruttering
- Local Site #056001
-
Leuven, Belgien, 3000
- Rekruttering
- Local Site #056002
-
-
-
-
-
Montreal, Canada, H4A 3J1
- Ikke rekrutterer endnu
- Local Site #840102
-
Ottawa, Canada, K1Y 4S7
- Rekruttering
- Local Site #840101
-
-
-
-
-
London, Det Forenede Kongerige, W1G 9ST
- Ikke rekrutterer endnu
- Local Site #300001
-
-
-
-
California
-
La Jolla, California, Forenede Stater, 92037
- Rekruttering
- Site Location #840023
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- Local Site #840014
-
-
Florida
-
Saint Augustine, Florida, Forenede Stater, 32086
- Rekruttering
- Local Site #840016
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Local Site #840008
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Local Site #840010
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905-0002
- Rekruttering
- Local Site #840005
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Local Site #840020
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Local Site #840017
-
-
Texas
-
Houston, Texas, Forenede Stater, 77034
- Rekruttering
- Local Site #840001
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Local Site #840019
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84132
- Rekruttering
- Local Site #840013
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05401
- Rekruttering
- Local Site #840022
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Local Site #840004
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- Local Site #840018
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98105
- Rekruttering
- Local Site #840021
-
-
-
-
-
Paris, Frankrig, 75013
- Ikke rekrutterer endnu
- Local Site #250001
-
Pessac, Frankrig, 33600
- Ikke rekrutterer endnu
- Local Site #250002
-
Toulouse, Frankrig, 31059
- Ikke rekrutterer endnu
- Local Site #250003
-
Toulouse, Frankrig, 31400
- Ikke rekrutterer endnu
- Local Site #250004
-
-
-
-
-
Athens, Grækenland, 11527
- Ikke rekrutterer endnu
- Local Site #300002
-
Athens, Grækenland, 16673
- Rekruttering
- Local Site #300001
-
-
-
-
-
Barcelona, Spanien, 08035
- Ikke rekrutterer endnu
- Local Site #724001
-
El Palmar, Spanien, 30120
- Ikke rekrutterer endnu
- Local Site #724002
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants are male or female ≥ 18 years up to ≤ 75 years of age.
- Capable of giving signed informed consent and able to comply with the protocol
- Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event
- Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.
- CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg/L must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)
- Pericarditis pain score ≥ 4 based on the 11-point NRS.
- Stable doses of NSAIDs, colchicine, and/or oral corticosteroids (if receiving these treatments)
Exclusion Criteria:
- Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.
- History of clinically significant immunosuppressive disorder, autoimmune/autoinflammatory disorder, or primary or secondary immunodeficiency.
- Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Kohorte A
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Kohort B -behandlingsgruppe B1
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Kohort B -behandlingsgruppe B2
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Cohort C Treatment Group C1
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
|
Eksperimentel: Cohort C Treatment Group C2
|
Dose A, Daily
Andre navne:
Dose B, Daily
Andre navne:
Dose C, Daily
Andre navne:
Dose D, Daily
Andre navne:
Dose E, Daily
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety and tolerability of VTX2735
Tidsramme: Day 1 of treatment period through study completion, up to 26 weeks
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation |
Day 1 of treatment period through study completion, up to 26 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Effect of VTX2735 on pericardial pain
Tidsramme: Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in Numeric Pain Rating Scale (NRS) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
|
Effect of VTX2735 on inflammation
Tidsramme: Day 1 of treatment period to Week 6 of treatment period
|
Change from baseline in High-Sensitivity C-Reactive Protein (hs-CRP) over time through Week 6 |
Day 1 of treatment period to Week 6 of treatment period
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 27930
- VTX2735-202 (Anden identifikator: Ventyx Biosciences, Inc.)
- J7W-MC-ELCA (Anden identifikator: Eli Lilly and Company)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .